Post Conference Perspectives: Trilaciclib, a New Option for Chemotherapy-Induced Myelosuppression
Ralph Boccia, MD and Jim Schwartz, RPh provide key insights into the recent FDA approval of trilaciclib and discuss its impact on the treatment landscape for extensive-stage small cell lung cancer.
EP. 1: Impact of Myelosuppression in Extensive-Stage SCLC
Jim Schwartz, RPh, National Community Oncology Dispensing Association, Inc.
Ralph Boccia, MD, discusses myelosuppression with chemotherapy and highlights its impact on treatment outcomes and patient quality of life.
EP. 2: Trilaciclib in SCLC: Mechanism of Action and Dosage
Jim Schwartz, RPh, National Community Oncology Dispensing Association, Inc.
Jim Schwartz, RPh, provides key insights into the recent approval of trilaciclib and discusses how CDK4/6 inhibition potentially improves response to cytotoxic chemotherapy by protecting patients from myelosuppression.
EP. 3: Registrational Trials for the FDA Approval of Trilaciclib
Jim Schwartz, RPh, National Community Oncology Dispensing Association, Inc.
An expert in the management of small cell lung cancer gives an in-depth review of the study design, safety, and efficacy of the clinical trials that led to the FDA approval of trilaciclib for chemotherapy-induced myelosuppression.
EP. 4: Potential Adverse Effects of Trilaciclib
Jim Schwartz, RPh, National Community Oncology Dispensing Association, Inc.
Ralph Boccia, MD, and Jim Schwartz, RPh, build a discussion on the potential adverse effects of trilaciclib, including fatigue, hypocalcemia, hypokalemia, injection site reactions, pneumonitis, and interstitial lung disease.
EP. 5: Impact of Trilaciclib on the Treatment Landscape
Jim Schwartz, RPh, National Community Oncology Dispensing Association, Inc.
Ralph Boccia, MD, and Jim Schwartz, RPh, discuss the overall impact the approval for trilaciclib will have on patients’ treatment outcomes, health care expenses, and quality of life.
